Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8.
In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company’s website. The company description (in Swedish) is also available at Vitrolife’s webpage www.vitrolife.com/corporate.
October 4, 2012
VITROLIFE AB (publ)
Queries should be addressed to:
Thomas Axelsson, CEO, phone 46 31 721 80 01
Mikael Engblom, CFO, phone 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 4, 2012 at 08.30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.